We describe the clinical courses and outcomes of allogeneic hematopoietic stem cell transplantation-associated organizing pneumonia (HOP) observed in our institution over the past 20 years. Charts and chest radiographs of 603 allogeneic transplant recipients were retrospectively reviewed for HOP. In total, 12 cases of HOP were identified (2.0%) at a median interval of 148 days after transplantation (range, 53-475 days), presenting with low-grade fever, nonproductive cough and dyspnea at onset. Initial antibiotic treatment did not ameliorate symptoms, but most patients responded well to 0.5-1 mg/kg of prednisolone. HOP flare-up occurred after discontinuing treatment or while tapering doses in 9 of 12 patients, but responded to re-treatment with the initial dose of steroid. Although three patients died, no deaths were attributable to pulmonary failure. The remaining nine patients displayed no relapse of primary disease and 5-year survival rate was 74.1%. Clinical features of the 12 patients were similar in that all underwent irradiationcontaining conditioning and most had a prior history of acute graft-versus-host disease (GVHD) and cytomegalovirus (CMV) infection. Furthermore, eight patients had active chronic GVHD at onset of HOP. These findings suggest that factors such as irradiation-containing regimens, previous CMV infection and allogeneic immune reaction may contribute to HOP occurrence.
Introduction
Although encouraging survival statistics are now reported after hematopoietic stem cell transplantation (HSCT), pulmonary complications occur in up to half of patients after HSCT and represent major causes of morbidity and mortality. [1] [2] [3] [4] While infectious processes are a major source of such pulmonary complications, late-onset non-infectious pulmonary complications (LONIPCs) are also frequently encountered. [5] [6] [7] Organizing pneumonia may develop after HSCT, possibly representing a pulmonary presentation of chronic graft-versus-host disease (GVHD). [8] [9] [10] [11] Organizing pneumonia has been included in older reports under different names such as 'bronchiolitis obliterans organizing pneumonia (BOOP)'. However, the term BOOP may mistakenly suggest a major physiological role for bronchiolitis obliterans, a clinical entity that differs from organizing pneumonia in radiological, functional and clinical features. 12 A recently published classification of idiopathic interstitial pneumonias developed by an international panel has proposed the term 'cryptogenic organizing pneumonia' (COP). 13 However, both clinically and etiologically, the term 'cryptogenic' may not be accurate in cases occurring after HSCT, so to avoid confusion, we have used the term hematopoietic stem cell transplantation-associated organizing pneumonia (HOP) rather than COP in this report. The first case of HOP was described by Thirman et al. in 1992. 14 Although subsequent publications on HOP have largely been limited to case reports, accumulated case series have now disclosed distinct clinical and prognostic features compared to other life-threatening diseases belonged to LONIPC. 7 The goals of this study were to describe the clinical courses and outcomes for 12 cases of HOP among 603 allogeneic transplant cases performed over the last 20 years in a single institution.
Patients and methods

Patients
We retrospectively reviewed 603 patients (361 men, 242 women; median age 37 years; range 15-68 years) with various diseases who underwent allogeneic transplantation (460 bone marrow transplantations: 224 related, 236 unrelated; 96 related peripheral blood stem cell transplant-ations; 47 unrelated cord blood stem cell transplantations) between September 1986 and December 2005. Underlying diseases were chronic myeloid leukemia (n ¼ 134), acute nonlymphoid leukemia (n ¼ 154), acute lymphoid leukemia (n ¼ 131), myelodysplastic syndrome (n ¼ 88), severe aplastic anemia (n ¼ 37), non-Hodgkin's lymphoma (n ¼ 27), myelofibrosis (n ¼ 5), multiple myeloma (n ¼ 13), adult T-cell leukemia/lymphoma (n ¼ 2), pancreatic cancer (n ¼ 6), gastric cancer (n ¼ 2), rectal cancer (n ¼ 1), gallbladder cancer (n ¼ 1), bile duct cancer (n ¼ 1) and Ewing's sarcoma (n ¼ 1).
Preparative regimen, GVHD prophylaxis, infection prophylaxis and cytomegalovirus monitoring Preparative therapy was basically performed according to the primary disease and type of transplant. Generally, patients with lymphoid malignancy were conditioned using a total body irradiation (TBI; 12 Gy)-containing regimen, including cytarabine (8 g/m 2 ) and cyclophosphamide (CY, 120 mg/kg). TBI was performed with partial transmission anterior-posterior lung 33% shielding. Conversely, patients with myeloid malignancy were conditioned using a non-TBI-containing regimen that included busulfan (BU, 16 mg/kg) and CY (120 mg/kg). Plasma concentrations of busulfan were not monitored. Total lymphoid irradiation (TLI, 7Gy) was included in BU/CY regimens in cases with mismatch or unrelated transplantation. Patients with severe aplastic anemia were also conditioned using a TLI-containing regimen. Patients with solid cancer underwent nonmyeloablative allogeneic stem cell transplantation with preparative conditioning comprising CY (120 mg/kg) and fludarabine (125 mg/m 2 ). Cyclosporine (CyA) or tacrolimus (FK) plus short-term methotrexate were used for GVHD prophylaxis. FK was used in cases involving either unrelated or mismatched transplantation. Acute and chronic GVHD were diagnosed and graded according to previously established criteria. 15, 16 Tosulfloxacin and fluconazol were orally administered 14 days before HSCT. Trimethoprim-sulfamethoxazole (TMP 240 mg, SMX 1200 mg; 3 times/week) was also used to prevent PneumoCystis pneumonia. Cytomegalovirus (CMV) infection was monitored weekly by CMV antigenemia. Positive antigenemia, defined as 41 cell/65 000 cells, was treated using ganciclovir twice daily until negative CMV antigenemia was obtained.
Diagnosis of HOP
Of the 603 HSCT recipients, 526 patients who survived 3 months after HSCT underwent initial review for HOP. Previously described disease definitions of HOP were used in this study. 17, 18 Symptomatic patients with bilateral air space disease, particularly those not responding to antibiotics for presumed pneumonia, were all classified as possibly displaying HOP. To exclude infection, standard culture and staining methods for bacterial, viral and protozoan pathogens were employed. Bronchoalveolar lavage (BAL) and transbronchial lung biopsy (TBLB) were also performed, but concomitant thrombocytopenia prohibited these invasive examinations in some patients. Most patients underwent pulmonary function tests (PFTs) or high-resolution computed tomography (HRCT) of the chest performed before conditioning therapy and at regular intervals after HSCT. PFTs typically showed a restrictive defect, with percent forced vital capacity (FVC) of the predicted value (%FVC) o80% and forced expiratory volume in 1 s (FEV 1 )/FVC X70%. HRCT typically showed peripherally distributed patchy airspace consolidation, ground-glass attenuation and nodular opacities.
Survival
Overall survival and relapse-free survival rate were estimated by Kaplan-Meier product-limit estimates. The log-rank test was used to assess differences between the groups of patients with and without HOP. A P-value of less than 0.05 was considered to be statistically significant.
Results
Clinical features of HOP
Of the 603 HSCT recipients, 12 patients (2.0%) were ultimately diagnosed with HOP at a median of 148 days (range, 53-475 days) after HSCT. Clinical characteristics of these 12 patients are summarized in Table 1 . Median age was 37 years (range, 19-52 years), and eight patients were men (67%). Most patients underwent unrelated HSCT (10 patients) with an irradiation-containing regimen. A history of acute GVHD was apparent in one patient and eight patients displayed active chronic GVHD (six extensive and two limited) at the onset of HOP. Pulmonary symptoms developed in the setting of steroid taper, as most patients were receiving steroid for GVHD (Table 2) . Initial symptoms were fever (eight patients) and cough (nine patients), and five patients also complained of mild to moderate dyspnea (Table 2 ). All patients failed to respond to empirical antibiotic treatment. Decreased serum immunoglobulin levels were observed in eight patients. Chest HRCT for HOP typically exhibited bilateral areas of patchy consolidation and ground glass opacities (GGO) (Figures 1b and c) . Nine patients showed patchy consolidation with or without GGO, while three patients showed nodular opacities (Table 2 ). These abnormalities were likely to display a focal or multifocal distribution (nine patients), but were less frequently diffuse (three patients). Two patients had episodes of prior pulmonary disease (druginduced interstitial pneumonia, n ¼ 1; bronchial asthma, n ¼ 1) and six patients had a previous history of smoking (Table 1) . A preceding history of positive cytomegalovirus antigenemia was present in nine patients for a median of 119 days (range, 75-308 days) before respiratory symptoms emerged. All 12 patients were conditioned with irradiationcontaining regimens; seven patients received TLI-containing and 5 patients received TBI-containing regimen.
BAL and TBLB were performed in eight and seven patients, respectively, and all examined specimens were submitted for microorganism culture, yielding negative results for bacteria (including Legionella, Nocardia and acid-fast bacilli), fungi, parasites (Pneumocystis jiroveci pneumonia) and viruses (CMV, respiratory syncytial, parainfluenza). At diagnosis, BAL showed hypercellularity with lymphocytosis (420% lymphocytes and decreased 
Management and outcome
All patients with HOP were treated using steroid after several days of antibiotics therapy yielded no improvement. Of those, 75% received initial doses of p1 mg/kg/day (Table 3) . Three patients with respiratory failure eventually required a bulk dose of corticosteroids (1 g/day of methylprednisolone for 3 days followed by 1 mg/kg/day of prednisolone). Most patients exhibited initial good response, but HOP relapse occurred in nine patients during steroid tapering (n ¼ 5) or within a few months after discontinuing steroids (n ¼ 4). These nine patients showed good response to re-treatment at initial steroid dose, although two patients experienced second episodes of disease exacerbation (patients 4 and 6). Either clinical symptoms or radiological findings subsided within a median of 5.5 days (range, 2-13 days). Results of chest radiography and HRCT normalized in six patients, while persistence of opacities on HRCT was seen in two patients. Death occurred in three cases, and causes of death were invasive aspergillosis (n ¼ 1), meningitis due to herpes simplex virus (n ¼ 1) and relapse of primary disease (n ¼ 1). No deaths were attributable to HOP. As of December 2006, nine patients remain alive. According to Kaplan-Meier product-limit estimates, 5-year overall survival was 74.1% ( Figure 2 ).
Discussion
This study demonstrated the incidence of HOP among 603 recipients of allogeneic HSCT. Although some patients might have been missed due to mild illness, the cumulative incidence of HOP in our series (2.0%) was equivalent to incidence rates reported by others using similar definitions and comparable diagnostic methods. 19 HOP may exhibit a multifactorial etiology, including toxic effects of myeloablative regimens, including irradiation, immunological cell-mediated injury, inflammatory cytokine-induced lung damage and occult pulmonary infections. Although the contribution made by each of these potential pulmonary insults to the pathogenesis of HOP remains obscure, emphasizing that 8 of 12 HOP patients displayed active chronic GVHD at the onset of HOP may be important. Patients with HOP were also more likely to experience chronic GVHD involving the skin and oral cavity in our series. All patients were receiving steroid, calcineurin inhibitor or both at the onset of HOP, and HOP arose during tapering of these immunosuppressive medicaments. Blood biochemistry tests performed on limited patients showed decreased immunoglobulin A and G antibody levels, suggesting that immunosuppression as a consequence of prior steroid treatment for GVHD may also play an important role in this condition. 20 In a recent casecontrol study, Freudenberger et al. 10 reviewed 49 cases of HOP and found an association between acute and chronic GVHD and subsequent development of HOP. Although further clarification is warranted, these findings suggest a causal relationship between chronic GVHD and HOP.
Irradiation is thought to represent an alternativecontributing factor to the development of HOP, as our HOP patients were all conditioned with irradiationcontaining regimens. Baron et al. 21 summarized eight previously reported cases of HOP and found that seven out of eight patients received TBI containing regimen. Of note is the fact that incidence of HOP was significantly higher in patients with irradiation-containing regimens than in patients with conventional conditioning regimens, such as those containing BU plus CY, for which no TLI is administered (12 of 342 patients versus 0 of 261 patients, respectively; Po0.005). Although the lung was actually outside of the irradiation field in the settings for TLI, radiation-induced inflammatory cytokine release may play a pivotal role in the development of HOP; for example, indirect radiation exposure may initiate lymphocyte stimulation, in turn leading to immunological reactions in the non-irradiated lung. The presence of lymphocytosis in BAL fluid supports the theory such as an initial radiationinduced injury 'primes' the lymphocytes, ultimately leading to development of HOP.
The absence of any microorganisms despite cultures of blood, sputum or BAL fluid and the failure of empirical antibiotics treatment excluded the possibility of active 
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infection at the onset of pulmonary symptoms in our patients. However, given that most patients showed a preceding episode of CMV reactivation within the time frame of HOP onset, it is tempting to speculate on a possible association between HOP and CMV reactivation, which has been among previously reported risk factors. 21 The etiology of HOP thus remains unclear, but may be complicated by several plausible factors, including direct immunological reaction, irradiation and underlying infection or aspiration.
HRCT appearances of HOP have been well described and were in keeping with previous descriptions of COP. 22 Most patients demonstrated consolidation, GGO and septal thickening. Consolidation and GGO were bilateral, patchy and asymmetrical, and predominantly peribronchovascular in distribution. Nodules were an uncommon manifestation in our series ( Table 2 ). The predominant PFT pattern was characterized by a restrictive component and was in accordance with data from the literature concerning COP. Analysis of blood gases indicated mild or major hypoxemia with normal pCO 2 values in most patients.
Consistent with previous reports, 18 clinical course of HOP in our series was better compared with that of other LONIPCs patients and most patients recovered without serious sequelae, with a 5-year overall survival rate of 74.1%. Among the 591 patients without HOP, 5-year overall survival was 61.9% ( Figure 2 ). The good outcomes in HOP may be primarily due to better clinical response to steroid therapy. Low-dose steroids have generally been advocated for treatment in HOP, 23, 24 but no studies of sufficient sample size have shown unequivocal benefit from this intervention. In our patients, high-dose steroid therapy was associated with worse outcomes due to opportunistic infection (Cases 7 and 12). Conversely, most patients maintained on lower-dose steroids remain alive despite facing HOP recurrence probably due to faster dose reductions of steroid within a median of 125 days. Dose and duration of steroid treatment may thus have been important in terms of improved outcome, as nine patients with first recurrence were on gradual dose reduction over a longer duration (median, 210 days), and only two of these patients faced a second recurrence of HOP. Sakaida et al. 25 observed that patients with LONIPCs experienced significantly lower relapse rates of primary malignant disease than non-LONIPCs patients, but overall survival of the former group was not longer, because most LONIPCs patient died of progressive respiratory failure. However, this may not be true in patients with HOP, since the benefit of anti-leukemic reactions was not counterbalanced by progression of respiratory failure as in other LONIPCs.
This study has several limitations. Owing to the retrospective nature of this study, we might have missed some patients, despite the detailed database and extensive chart review. Moreover, our study may be flawed in obtaining pathological evidences for HOP. Histological confirmation of HOP was mainly performed by TBLB rather than open lung biopsy. Open lung biopsy is generally considered the golden standard tool for the diagnosis of LONIPCs and for the subclassification of the different pathological entities, in particular, HOP. 18 It may be impossible to determine whether organizing pneumonia on a transbronchial biopsy is the primary process or simply a secondary phenomenon. Nevertheless, our focus was to outline the clinical courses and outcomes of HOP among 603 allogeneic transplant cases performed over the last 20 years in a single institution.
In conclusion, development of HOP might be associated with irradiation, previous CMV infection and chronic GVHD. The HRCT features of HOP were bilateral, patchy and asymmetric area of consolidation as well as patchy and asymmetric GGO. Treatment with low-dose steroid was well tolerated and most patients achieved a durable response; however, faster dose reductions of steroid resulted in disease exacerbation. Although further study is warranted, our data should provide useful insights into this disease. Clinical feature of HOP M Jinta et al
